- Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment
-
Park SY, Ahn SH, Yoo JI, Chung YJ, Jeon YK, Yoon BH, Kim HY, Lee SH, Lee J, Hong S
- KMID: 2465023
- J Bone Metab.
- 2019 Nov;26(4):213-224.
- doi: 10.11005/jbm.2019.26.4.213
Current evidences continue to support the clinical application of bone turnover markers (BTMs) in the management of postmenopausal osteoporosis. The limitations of bone mineral density measured by dual energy X-ray... -
- CITED
-
- Close
- SHARE
-
- Close
- Silencing of LncRNA-ANCR Promotes the Osteogenesis of Osteoblast Cells in Postmenopausal Osteoporosis via Targeting EZH2 and RUNX2
-
Cai N, Li C, Wang F
- KMID: 2452956
- Yonsei Med J.
- 2019 Aug;60(8):751-759.
- doi: 10.3349/ymj.2019.60.8.751
PURPOSE: This study aimed to explore the effects and mechanisms of long non-coding RNA (lncRNA) anti-differentiation non-coding RNA (ANCR) on the osteogenesis of osteoblast cells in postmenopausal osteoporosis (PMOP). MATERIALS AND... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Parity and Breastfeeding Duration on Bone Density in Postmenopausal Women
-
Lee EN
- KMID: 2449398
- Asian Nurs Res.
- 2019 May;13(2):161-167.
- doi: 10.1016/j.anr.2019.04.002
PURPOSE: This study aimed to identify the effect of parity and breastfeeding duration and the occurrence of lumbar vertebral and femoral neck osteoporosis in Korean postmenopausal women. METHODS: This study analyzed... -
- CITED
-
- Close
- SHARE
-
- Close
- SPA0355 prevents ovariectomy-induced bone loss in mice
-
Kim SH, Zhang Z, Moon YJ, Park IW, Cho YG, Jeon R, Park BH
- KMID: 2443615
- Korean J Physiol Pharmacol.
- 2019 Jan;23(1):47-54.
- doi: 10.4196/kjpp.2019.23.1.47
Estrogen withdrawal in post-menopausal women leads to overactivation of osteoclasts, which contributes to the development of osteoporosis. Inflammatory cytokines are known as one of mechanisms of osteoclast activation after estrogen... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Childbirth Age on Bone Mineral Density in Postmenopausal Women
-
We JS, Han K, Kwon HS, Kil K
- KMID: 2426664
- J Korean Med Sci.
- 2018 Nov;33(48):e311.
- doi: 10.3346/jkms.2018.33.e311
BACKGROUND: In postmenopausal women, there is rapid bone loss due to estrogen depletion. In women, reproductive factors such as age at menarche, breastfeeding, and parity are considered risk factors of... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation
-
Tanaka M, Itoh S, Takeuchi Y
- KMID: 2437291
- Osteoporos Sarcopenia.
- 2018 Sep;4(3):111-117.
- doi: 10.1016/j.afos.2018.08.002
OBJECTIVES: We compared the effectiveness of bisphosphonates combined with activated vitamin D administered for therapy of aromatase inhibitor-induced osteoporosis after a breast cancer operation and primary postmenopausal osteoporosis through propensity... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of isoflavone-enriched whole soy milk powder supplementation on bone metabolism in ovariectomized mice
-
Kim SM, Lee HS, Jung JI, Lim SM, Lim JH, Ha WH, Jeon CL, Lee JY, Kim EJ
- KMID: 2420992
- Nutr Res Pract.
- 2018 Aug;12(4):275-282.
- doi: 10.4162/nrp.2018.12.4.275
BACKGROUND/OBJECTIVE: There is intense interest in soy isoflavone as a hormone replacement therapy for the prevention of postmenopausal osteoporosis. A new kind of isoflavone-enriched whole soy milk powder (I-WSM) containing... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
-
Suzuki T, Nakamura Y, Kato H
- KMID: 2437849
- Osteoporos Sarcopenia.
- 2018 Jun;4(2):67-70.
- doi: 10.1016/j.afos.2018.04.001
OBJECTIVES: The aim of this study was to examine the efficacy, safety, and adherence of ibandronate (IBN) treatment with or without vitamin D supplementation for 3 years in Japanese women... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between Bone Mineral Density and Albuminuria: Cross-Sectional Analysis of Data from the 2011 Korea National Health and Nutrition Examination Survey V-2
-
Yu TY, Kim HY, Lee JM, Lee DH, Cho CG
- KMID: 2420489
- Endocrinol Metab.
- 2018 Jun;33(2):211-218.
- doi: 10.3803/EnM.2018.33.2.211
BACKGROUND: Albuminuria is known to be independently associated with progression of renal and cardiovascular disease. However, little is known regarding the exact relationship between albuminuria and bone mineral density (BMD).... -
- CITED
-
- Close
- SHARE
-
- Close
- The Changes of CTX, DPD, Osteocalcin, and Bone Mineral Density During the Postmenopausal Period
-
Park SG, Jeong SU, Lee JH, Ryu SH, Jeong HJ, Sim YJ, Kim DK, Kim GC
- KMID: 2417836
- Ann Rehabil Med.
- 2018 Jun;42(3):441-448.
- doi: 10.5535/arm.2018.42.3.441
OBJECTIVE: To investigate appropriate treatment time and useful bone turnover markers (BTMs) for monitoring bone turnover during the postmenopausal period, we analyzed changes of two bone resorption markers; serum carboxyterminal... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-Effectiveness of Denosumab for Post-Menopausal Osteoporosis in South Korea
-
Bae G, Kwon HY
- KMID: 2416672
- Korean J Clin Pharm.
- 2018 Jun;28(2):131-137.
- doi: 10.24304/kjcp.2018.28.2.131
BACKGROUND: In South Korea, 22.3% of women ≥50 years of age and 37% of women ≥70 years of age visit the doctor to obtain treatment for osteoporosis. According to the... -
- CITED
-
- Close
- SHARE
-
- Close
- Romosozumab for the treatment of osteoporosis
-
McClung MR
- KMID: 2437854
- Osteoporos Sarcopenia.
- 2018 Mar;4(1):11-15.
- doi: 10.1016/j.afos.2018.03.002
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of... -
- CITED
-
- Close
- SHARE
-
- Close
- An Ovariectomy-Induced Rabbit Osteoporotic Model: A New Perspective
-
Wanderman , Mallet C, Giambini H, Bao N, Zhao C, An KN, Freedman B, Nassr A
- KMID: 2403591
- Asian Spine J.
- 2018 Feb;12(1):12-17.
- doi: 10.4184/asj.2018.12.1.12
STUDY DESIGN: Experimental Animal Model. PURPOSE: The aim of our study was to validate a pure bilateral ovariectomy (OVX) female New Zealand white rabbit model of postmenopausal osteoporosis utilizing animal-sparing in... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiosteoporotic activity of Salvadora persica sticks extract in an estrogen deficient model of osteoporosis
-
Fouda AM, Youssef AR
- KMID: 2395000
- Osteoporos Sarcopenia.
- 2017 Sep;3(3):132-137.
- doi: 10.1016/j.afos.2017.07.002
OBJECTIVES: The effect of Salvadora persica sticks on prevention of tooth decay is well established, but the effect of S. persica stick extract (SPE) on the prevention/treatment of osteoporosis has... -
- CITED
-
- Close
- SHARE
-
- Close
- Protective effect of Rhus verniciflua Stokes extract in an experimental model of post-menopausal osteoporosis
-
Jeong JH, An JH, Yang H, Kim DK, Lee NS, Jeong YG, Na CS, Na DS, Dong MS, Han SY
- KMID: 2390484
- Anat Cell Biol.
- 2017 Sep;50(3):219-229.
- doi: 10.5115/acb.2017.50.3.219
Post-menopausal osteoporosis (PMO) is a major global human health concern. Owing to the need for therapeutic drugs without side effects, natural extracts containing various polyphenolic compounds that may exert estrogenic... -
- CITED
-
- Close
- SHARE
-
- Close
- An Overview of the Clinical Efficacy and Safety of Tissue Selective Estrogen Complex: From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials
-
Chun SW
- KMID: 2384829
- Kosin Med J.
- 2017 Jun;32(1):5-16.
- doi: 10.7180/kmj.2017.32.1.5
Hormone therapy (HT) is the most effective treatment for menopausal symptoms, and reduces both spinal and non-spinal postmenopausal osteoporotic fractures. However, a Women's Health Initiative (WHI) trial revealed that progestin-containing... -
- CITED
-
- Close
- SHARE
-
- Close
- Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
-
Ohtori S, Orita S, Yamauchi K, Eguchi Y, Aoki Y, Nakamura J, Suzuki M, Kubota G, Inage K, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue M, Kinoshita , Furuya T, Koda M
- KMID: 2377761
- Asian Spine J.
- 2017 Apr;11(2):272-277.
- doi: 10.4184/asj.2017.11.2.272
STUDY DESIGN: Retrospective case series. PURPOSE: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass... -
- CITED
-
- Close
- SHARE
-
- Close
- Denosumab for the treatment of osteoporosis
-
McClung MR
- KMID: 2376998
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):8-17.
- doi: 10.1016/j.afos.2017.01.002
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of... -
- CITED
-
- Close
- SHARE
-
- Close
- Change of Bone Mineral Density and Relationship to Clinical Parameters in Male Stroke Patients
-
Kim HD, Kim SH, Kim DK, Jeong HJ, Sim YJ, Kim GC
- KMID: 2371329
- Ann Rehabil Med.
- 2016 Dec;40(6):981-988.
- doi: 10.5535/arm.2016.40.6.981
OBJECTIVE: To investigate the clinical characteristics that significantly contribute to a decreased bone mineral density (BMD), the BMD changes and clinical characteristics of men who experienced a stroke between the... -
- CITED
-
- Close
- SHARE
-
- Close
- Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels
-
Engin-Üstün Y, Çağlayan EK, Göçmen A, Polat MF
- KMID: 2365462
- J Menopausal Med.
- 2016 Aug;22(2):76-79.
- doi: 10.6118/jmm.2016.22.2.76
OBJECTIVES: The objective of this study was to describe the levels of chemerin, irisin and apolipoprotein M (apoM) in women with postmenopausal osteoporosis. METHODS: The study included 88 women with postmenopausal... -
- CITED
-
- Close
- SHARE
-
- Close
